Addex Wins Michael J. Fox Foundation Funding To Take Its Dopamine Side Effect Therapy Into Phase II Testing
This article was originally published in The Pink Sheet Daily
Executive Summary
After a costly 2009 setback, venture philanthropy steps in to help Addex move a risky program forward.
You may also be interested in...
Positive Early Results For Addex Parkinson’s Drug Dipraglurant Spur Hopes For Deal
In a small, short Phase IIa study, an oral inhibitor of mGluR5 proved effective at reducing dyskinesia caused by levodopa. If future trials are positive, the drug would have a significant positive impact on Parkinson’s patients, says the Michael J. Fox Foundation.
Positive Early Results For Addex Parkinson’s Drug Dipraglurant Spur Hopes For Deal
In a small, short Phase IIa study, an oral inhibitor of mGluR5 proved effective at reducing dyskinesia caused by levodopa. If future trials are positive, the drug would have a significant positive impact on Parkinson’s patients, says the Michael J. Fox Foundation.
NIBR Model Improves Novartis Early Pipeline Success Rate
Eight years after Novartis AG launched the Novartis Institutes for Biomedical Research under Harvard Medical School cardiologist Mark Fishman and let him design a novel strategy for vetting early-stage projects, the company's Phase II success rate for new molecular entities has doubled.